News
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...
WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug ...
FDA awards Novartis expanded approval for breast cancer therapy Kisqali OK’d for certain early-stage breast cancers, enlarging the drugmaker’s potential market Manage alerts for this article ...
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback